Lyme disease: impact of the CDC surveillance criteria on patients

Townsend Letter for Doctors and Patients, June, 2004 by Marcus A. Cohen

3. Weintraub P, Conflicts of interest in Lyme disease, LDA (Jackson, New Jersey), 2001.

4. Bakken LL et al., Interlaboratory comparison of test results for detection of Lyme disease by participants in the Wisconsin State Laboratory of Hygiene/College of American Pathologists Proficiency Testing Program, J Clin Microbiol, 1997;35(3):537-543.

5. Harris NS, An understanding of laboratory testing for Lyme disease, J Spirochetal & Tick-borne Diseases, 1998, Vol 5 (Spring/Summer):16-26.

6. NIAID, NIAID collaboration yields new test for Lyme disease, NIH News Advisory, 6/18/01.

7. Aguero-Rosenfeld ME et al., Evolution of the serologic response to Borrelia burgdorferi in treated patients with culture-confirmed erythema migrans, J Clin Microbiol, 1996:34(1):1-9. Also: Aguero-Rosenfeld ME et al., Serodiagnosis in early Lyme disease, J Clin Microbiol, 1993;31(12):3090-3095.

8. Rawlings JA et al., Isolation of Borrelia Spirochetes from patients in Texas, J Clin Microbiol, 1987;25(7):1148-1150.

9. Donta ST, Tetracycline therapy for chronic Lyme disease, Clin Infect Dis, 1997;25 Suppl 1:S52-S56

10. NIAID Diagnosis of Lyme disease: available at http://www.niaid.nih.gov/dmid/lyme/diagnosis.htm.> 11. FDA, Lyme disease test kits: potential for misdiagnosis, FDA Medical Bulletin, 1999; Summer (Final Issue).

12. Johnson L et al., Treatment of tick-borne diseases: a medicolegal assessment, publication pending.

13. Departments of Labor, Health & Human Services, Education, & Related Agencies Appropriations Act 2002.

by Marcus A. Cohen

8 East 96th Street #1C * New York, New York 10128 212-427-0707 * Fax 212-348-8288

COPYRIGHT 2004 The Townsend Letter Group

COPYRIGHT 2004 Gale Group